- Citations, last 5 years
- 356.5k
- Works, last 5 years
- 25.4k
- h-index
- 1,797
- Scientists listed
- 655
- Grants since 2016
- 3 144
Grants received
2023–2027 · award
Identifying determinants of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia with Down syndrome
Lisa Jacola · Dana-Farber Cancer Institute · funded by American Cancer Society
2023–2026 · grant · PCRP
Targeting Delta-Like Ligand 3 (DLL3) in Neuroendocrine Prostate Cancer
Himisha Beltran · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2023–2026 · career development · K23
Development and Pilot Testing of a Collaborative Agenda-Setting Intervention to Promote Patient-Centered Communication in Ovarian Cancer Care
Rachel Pozzar · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · research · R01
Disparities in Clinical Trial Enrollment among Adolescents and Young Adults with Cancer
Jennifer W Mack · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2026 · grant · DP2
Engineering programmable enzymes for proteome editing
Xin Zhou · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2024 · cooperative agreement · U01
The construction and utility of reference pan-genome graphs
Heng Li · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023 · research · Research
Comparison of Two Lifestyle Interventions To Improve Cognitive and Physical Function Among Older Cancer Survivors and Their Caregivers
Christina Dieli-Conwright · Dana-Farber Cancer Institute · funded by Patient-Centered Outcomes Research Institute
2023 · fellowship · F32
Characterization of LINE-1 reverse transcriptase activity
Benedict Smail · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · research · R01
Regulation of androgen receptor signaling in prostate cancer by protein arginine methylation
Srinivas Raghavan Viswanathan · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · program · P50
DF/HCC Prostate SPORE
Steven P. Balk · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2025 · award
Exercise for Gut Microbiome in Patients with Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial
Christina Dieli-Conwright · Dana-Farber Cancer Institute · funded by American Cancer Society
2023–2028 · research · R01
Mitoribosome protein translation signaling and survival mechanisms
Pere Puigserver · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · career development · K08
Improving response prediction to neoadjuvant therapy in pancreatic cancer
Harshabad Singh · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2030 · research · R35
Targeting Pediatric Cancer Vulnerabilities
Kimberly Stegmaier · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2026 · career development · K23
Development and Pilot Testing of a Collaborative Agenda-Setting Intervention to Promote Patient-Centered Communication in Ovarian Cancer Care
Rachel Pozzar · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · research · R01
Molecular mechanisms of splicing dependency in cohesin-mutant myelodysplasia
Zuzana Tothova · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2025 · cooperative agreement · UG3
Single Molecule Detection of L1 Insertions and Intermediates
Bradley Evan Bernstein · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · research · R01
Targeting SHP-1 through a newfound metabolite-regulated cysteine activation site
Edward Thomas Chouchani · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2024 · cooperative agreement · U01
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
Robert J Gray · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · cooperative agreement · U54
A digital twin to track and predict the evolution of pediatric neuroblastoma tumors
Franziska Michor · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2026 · grant · KCRP
Mechanisms and Predictors of Adoptive Cytokine-Induced Memorylike NK Cell Therapy in Renal Cell Carcinoma
Rizwan Romee · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2023–2027 · grant · PCRP
Tumor Immunotherapy by Gene-Circuit Engineered Response (TIGER) for Neuroendocrine Prostate Cancer
Ming-Ru Wu · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2023–2026 · grant · PRCRP
Exploring the Regulatory Landscape of Pediatric vs Adult Germ Cell Tumors in a Developmental Framework to Gain New Therapeutic Insights
Anne Frazier · Dana-Farber Cancer Institute · funded by Congressionally Directed Medical Research Programs
2023–2028 · award
MyPref: A Communication and Decision Tool for Adolescents and Young Adults with Advanced Cancer
Jennifer Snaman · Dana-Farber Cancer Institute · funded by American Cancer Society
2023–2025 · cooperative agreement · UG3
Single molecule detection of L1 insertions and intermediates
Bradley Evan Bernstein · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2027 · award
Cancer as a systemic disease
Kornelia Polyak · Dana-Farber Cancer Institute · funded by American Cancer Society
2023–2026 · fellowship · F32
Targeting the cancer neo-genome for destruction with CRISPR-Cas enzymes
Mitchell L Leibowitz · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2024 · research · R21
Formation and function of pathologic stress granules containing RNA-Binding Protein SFPQ in tauopathy
Rosalind A. Segal · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2027 · research · R01
Probing functional HIV-1 envelope glycoprotein conformations with novel potent CD4-mimetic compounds
Wayne A. Hendrickson · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2024 · cooperative agreement · U24
Human Tumor Atlas Network: Data Coordinating Center Extension
Ethan Cerami · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · cooperative agreement · U01
Immunotherapeutic targeting of gangliosides in Ewing Sarcoma
Robbie G. Majzner · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2028 · research · R01
BOLSTER: Strengthening Patient and Caregiver Supports in Advanced Gynecologic and Gastrointestinal Cancers - a Multi-Site Randomized Controlled Trial
Alexi A Wright · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2025 · research · R01
The Promoting Resilience in Stress Management (PRISM) Intervention: a multi-site randomized controlled trial for Adolescents and Young Adults with advanced cancer
Abby R Rosenberg · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2025 · award
Pediatric RISE: Pilot Randomized Feasibility of a Novel Universal Basic Income Health Equity Intervention
Kira Bona · Dana-Farber Cancer Institute · funded by American Cancer Society
2023–2028 · research · R01
Consequences of retrotransposition on genome integrity
Kathleen H Burns · Dana-Farber Cancer Institute · funded by National Institutes of Health
2023–2026 · award
Profiling tumor proteolysis with genetically-encoded signaling integrators
Itay Algov · Dana-Farber Cancer Institute · funded by Human Frontier Science Program
2023 · research · PCF Young Investigator Award
Defining Lineage-Specific PRC2 Action and Rational Co-Targeting of EZH1/2 in Prostate Cancer
Varadha Balaji Venkadakrishnan · Dana-Farber Cancer Institute · funded by Prostate Cancer Foundation
2023 · research · PCF Young Investigator Award
Uncovering Novel Biomarkers in Localized Prostate Cancer Through Radiomics and Digital Pathology
David D. Yang · Dana-Farber Cancer Institute · funded by Prostate Cancer Foundation
2023 · research · PCF Challenge Award
Darolutamide to Augment Radiotheranostic Therapy in Biochemically Recurrent Prostate Cancer (DART-BCR)
Praful Ravi · Dana-Farber Cancer Institute · funded by Prostate Cancer Foundation
2023 · research
Investigating endocrine therapy treatments for men with breast cancer
Jose Pablo Leone · Dana-Farber Cancer Institute · funded by Breast Cancer Research Foundation
